Nuvation Bio Inc. (NUVB)Healthcare | Biotechnology | New York, United States | NYSE
5.90 USD
+0.13
(2.253%)
⇧
(July 14, 2026, 4 p.m.
EDT)
After hours: 5.88 -0.02 (-0.020%) ⇩ (July 14, 2026, 7:57 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:52 a.m. EDT
The long-term investment case is severely compromised by a brutal multi-year decline; the stock has lost over three-quarters of its value since 2021, with the most recent annual return being negative. While the company boasts impressive gross margins and a massive cash pile relative to debt, the relentless price erosion suggests the market views the current valuation as unjustified given the execution risks inherent in biotech development. The short-term outlook remains fragile; despite a recent bounce off the lows, the options market is screaming for downside protection, with traders buying deep out-of-the-money puts to guard against further collapse. The statistical forecast offers no directional clarity, leaving the trade entirely dependent on whether the company can prove its pipeline can deliver results soon enough to reverse the structural damage done to the share price. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.076284 |
| AutoETS | 0.076284 |
| MSTL | 0.077726 |
| AutoTheta | 0.078075 |
| MSTL_115 | 0.096859 |
| MSTL_84 | 0.125990 |
| MSTL_84_115 | 0.133450 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 8.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.193 |
| Excess Kurtosis | -0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 67.9 |
| Revenue per Share | 0.416 |
| Market Cap | 2,054,391,680 |
| Forward P/E | -98.33 |
| Beta | 1.53 |
| Profit Margins | -102.06% |
| Website | https://www.nuvationbio.com |
As of July 11, 2026, 2:52 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts expiring in late 2026 and early 2027. Call activity is concentrated in out-of-the-money strikes, suggesting a speculative hope for a recovery to $7.50, but the sheer volume of put buying indicates a dominant fear of further decline rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.7089202 |
| Address1 | 1,500 Broadway |
| Address2 | Suite 1401 |
| All Time High | 15.23 |
| All Time Low | 0.95 |
| Ask | 0.0 |
| Ask Size | 6,300 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 8,265,900 |
| Average Daily Volume3 Month | 5,995,232 |
| Average Volume | 5,995,232 |
| Average Volume10Days | 8,265,900 |
| Beta | 1.527 |
| Bid | 0.0 |
| Bid Size | 6,200 |
| Board Risk | 8 |
| Book Value | 0.919 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.9 |
| Current Ratio | 7.439 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.115 |
| Day Low | 5.743 |
| Debt To Equity | 67.9 |
| Display Name | Nuvation Bio |
| Earnings Call Timestamp End | 1,777,926,600 |
| Earnings Call Timestamp Start | 1,777,926,600 |
| Earnings Timestamp | 1,777,924,800 |
| Earnings Timestamp End | 1,777,924,800 |
| Earnings Timestamp Start | 1,777,924,800 |
| Ebitda | -148,214,000 |
| Ebitda Margins | -1.03613 |
| Enterprise To Ebitda | -11.724 |
| Enterprise To Revenue | 12.147 |
| Enterprise Value | 1,737,646,592 |
| Eps Current Year | -0.28 |
| Eps Forward | -0.06 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.0868 |
| Fifty Day Average Change | 0.8132 |
| Fifty Day Average Change Percent | 0.15986474 |
| Fifty Two Week Change Percent | 170.89203 |
| Fifty Two Week High | 9.75 |
| Fifty Two Week High Change | -3.85 |
| Fifty Two Week High Change Percent | -0.39487177 |
| Fifty Two Week Low | 2.08 |
| Fifty Two Week Low Change | 3.8200002 |
| Fifty Two Week Low Change Percent | 1.8365386 |
| Fifty Two Week Range | 2.08 - 9.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,598,448,600,000 |
| Float Shares | 254,657,511 |
| Forward Eps | -0.06 |
| Forward P E | -98.333336 |
| Free Cashflow | -100,037,872 |
| Full Exchange Name | NYSE |
| Full Time Employees | 307 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.90776 |
| Gross Profits | 129,851,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18586999 |
| Held Percent Institutions | 0.64865 |
| Implied Shares Outstanding | 348,201,971 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York. |
| Long Name | Nuvation Bio Inc. |
| Market | us_market |
| Market Cap | 2,054,391,680 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_639036735 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -145,994,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,009,125,372 |
| Number Of Analyst Opinions | 9 |
| Open | 5.79 |
| Operating Cashflow | -125,731,000 |
| Operating Margins | 0.046630003 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 332 208 6102 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.33898273 |
| Post Market Price | 5.88 |
| Post Market Time | 1,784,073,466 |
| Previous Close | 5.77 |
| Price Eps Current Year | -21.071428 |
| Price Hint | 2 |
| Price To Book | 6.4200215 |
| Price To Sales Trailing12 Months | 14.361755 |
| Profit Margins | -1.02061 |
| Quick Ratio | 7.038 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.13 |
| Regular Market Change Percent | 2.25303 |
| Regular Market Day High | 6.115 |
| Regular Market Day Low | 5.743 |
| Regular Market Day Range | 5.743 - 6.115 |
| Regular Market Open | 5.79 |
| Regular Market Previous Close | 5.77 |
| Regular Market Price | 5.9 |
| Regular Market Time | 1,784,059,203 |
| Regular Market Volume | 7,294,675 |
| Return On Assets | -0.17024 |
| Return On Equity | -0.3951 |
| Revenue Growth | 25.987 |
| Revenue Per Share | 0.416 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 347,201,971 |
| Shares Percent Shares Out | 0.15609999 |
| Shares Short | 54,363,151 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 53,671,108 |
| Short Name | Nuvation Bio Inc. |
| Short Percent Of Float | 0.2585 |
| Short Ratio | 6.59 |
| Source Interval | 15 |
| State | NY |
| Symbol | NUVB |
| Target High Price | 19.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 12.33333 |
| Target Median Price | 12.0 |
| Total Cash | 533,728,992 |
| Total Cash Per Share | 1.533 |
| Total Debt | 216,984,000 |
| Total Revenue | 143,046,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.5081 |
| Two Hundred Day Average Change | 0.39190006 |
| Two Hundred Day Average Change Percent | 0.071149774 |
| Type Disp | Equity |
| Volume | 7,294,675 |
| Website | https://www.nuvationbio.com |
| Zip | 10,036 |